Share Price, page-6215

Maybe a few of us are losing some perspective.

Consider the following:

- Neuren is still a speculative share with risk attached - the phase 2 trials are not guaranteed to be successful
- Many of us have an entry price below $1 and see the SP at many multiples of that (10-20 times)
- If someone was to invest in Neuren today for the first time, the potential upside is maybe only 2-3 times the investment
- What might the downside be if, for example, the Phelan McDermid trial tanks
- While Neuren is still attractive to some, many would have considered that they missed the boat and there are more attractive propositions out there

Also, the register is so tightly held, some existing funds are playing their games, there is a 6+ month window to find out results, most existing holders are fully loaded ..................